Why the study?
Does esmolol or labetalol pretreatment attenuate hyperdynamic states after electroconvulsive therapy in patients with cardiovascular risk factors?
Does esmolol or labetalol pretreatment attenuate hyperdynamic states after electroconvulsive therapy in patients with cardiovascular risk factors?
Both esmolol and labetalol effectively attenuate the hyperdynamic cardiovascular response to electroconvulsive therapy, with esmolol potentially preferred for larger doses due to its shorter duration of action on systolic blood pressure.
Supports esmolol or labetalol pretreatment to blunt ECT hemodynamic surges in at-risk patients; extends RCT evidence for beta-blockade in electroconvulsive therapy.
We studied 18 patients (age range, 53-90 yr) with at least one cardiovascular risk factor who were treated with electroconvulsive therapy (ECT) and compared effects of five pretreatments: no drug; esmolol, 1.3 or 4.4 mg/kg; or labetalol, 0.13 or 0.44 mg/kg. Each patient received all five treatments, during a series of five ECT sessions. Pretreatment was administered as a bolus within 10 s of induction or anesthesia. Doses of methohexital and succinylcholine were constant for the series of treatments and the assignment to no drug or to drug and dose was determined by randomized block design. Measurements of systolic and diastolic blood pressure (SBP, DBP) and heart rate (HR) were recorded during the awake state and 1, 3, 5, and 10 min after the seizure. The deviation of ST segments from baseline was measured by an electrocardiogram (ECG) monitor equipped with ST-segment analysis software. The results (mean +/- SEM) show that without pretreatment, there were significant (P<0.05) peak increases in SBP and HR (55 +/- 5 mm Hg and 37 +/- 6 bpm, respectively), recorded 1 min after the seizure. Comparable reductions (by approximately 50%) in these peak values were achieved after esmolol (1.3 mg/kg) or labetalol (0.13 mg/kg), and cardiovascular responses were nearly eliminated after the same drugs in doses of 4.4 and 0.44 mg/kg, respectively. The deviation of ST-segment values from baseline in any lead was not measurably influenced by either antihypertensive drug. SBP values were lower after labetalol 10 min after the seizure, but not after esmolol. Asystolic time after the seizure was not significantly longer with either drug. No adverse reactions were observed. Because SBP effects were still present 10 min after the seizure, esmolol may be preferred if administration of a large dose of a beta-adrenergic blocker is contemplated. (Anesth Analg 1995;80:557-61)
No takes yet. Share an insight, caveat, or question.
Castelli et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: